13F Pro

SEC Form 4 reporting owner

Gibson Christopher

Gibson Christopher has filed 24 Form 4 transactions reported between January 5, 2026 and June 5, 2026, as Director of RECURSION PHARMACEUTICALS, INC. and Director of PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

Name as filed: Gibson Christopher

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$305K
2 lines
Companies
2
with Form 4 filings
Latest transaction
Jun 5, 2026
transaction date

Roles and reported holdings

  • RXRXRECURSION PHARMACEUTICALS, INC.
    Jan 5, 2026 – Jun 5, 2026

    Director

    Held directly883,735 sh as of May 15, 2026 · Form 4

    24 months: $305K sold

  • PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    Mar 3, 2026 – Jun 3, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 24 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 5, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Jun 3, 2026PACBDirectorGrant or awardCode A · direct74,497—Form 4
May 22, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
May 15, 2026RXRXDirectorShares withheld for tax or exercise priceCode F · direct22,821$69K@ $3.04Form 4
May 7, 2026RXRXDirectorGiftCode G · direct20,000—Form 4
May 7, 2026RXRXDirectorOpen-market saleCode S · direct40,000$135K@ $3.37Form 4
May 7, 2026RXRXDirectorConversion of derivativeCode C · direct60,000—Form 4
Apr 22, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Apr 8, 2026PACBDirectorGrant or awardCode A · direct77,842—Form 4
Apr 8, 2026PACBDirectorGrant or awardCode A · direct57,473—Form 4
Apr 7, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Mar 23, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Mar 9, 2026RXRXDirectorConversion of derivativeCode C · direct20,000—Form 4
Mar 3, 2026PACBDirectorGrant or awardCode A · direct73,087—Form 4
Mar 3, 2026PACBDirectorGrant or awardCode A · direct53,913—Form 4
Feb 19, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Feb 17, 2026RXRXDirectorShares withheld for tax or exercise priceCode F · direct27,265$95K@ $3.49Form 4
Feb 6, 2026RXRXDirectorShares withheld for tax or exercise priceCode F · direct10,364$37K@ $3.56Form 4
Feb 6, 2026RXRXDirectorGrant or awardCode A · direct30,346—Form 4
Feb 4, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Jan 20, 2026RXRXDirectorConversion of derivativeCode C · direct40,000—Form 4
Jan 5, 2026RXRXDirectorGiftCode G · direct20,000—Form 4
Jan 5, 2026RXRXDirectorOpen-market saleCode S · direct40,000$170K@ $4.25Form 4
Jan 5, 2026RXRXDirectorConversion of derivativeCode C · direct60,000—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.